First Alpha DaRT Patients Treated in France as Part of Alpha DaRT™ Multicenter Skin Cancer Trial

JERUSALEM, May 23, 2022 /PRNewswire/ — Alpha Tau Medical (Nasdaq: DRTS) (Nasdaq: DRTSW), the developer of the pioneering alpha-radiation cancer therapy Alpha DaRT™, announced today that the first patients in its French multicenter trial for skin cancer were treated with Alpha DaRT, at the Leon Berard Center in Lyon, France by Dr. Pascal Pommier and his team. The Leon Berard Center specializes in radiotherapy for cancer and is affiliated with the National Federation of Cancer Centers in France – UNICANCER Group. Dr. Pommier is the Principal Investigator of the French multicenter study and has more than 20 years of experience in radiation oncology and leading clinical trials.

The trial is currently being conducted at six cancer centers in France, on patients with malignant cutaneous lesions (including SCC, BCC, lentigo maligna melanoma, and carcinosarcoma), and is evaluating two cohorts: (1) newly diagnosed patients (up to 49 subjects), and (2) patients with locally recurrent disease (36 subjects). The primary effectiveness endpoint is the assessment of the overall response rate using RECIST criteria, 9 to 11 weeks after Alpha DaRT source insertion.

Alpha Tau CEO Uzi Sofer remarked, “We are thrilled to have our first patients treated in this important French multicenter study, our first protocol assessing first-line treatment irrespective of other available standard-of-care therapies. I want to thank Dr. Pascal Pommier for leading the study and successfully delivering treatment to the first two Alpha DaRT patients in France.”

“It is very exciting to offer an innovative treatment, such as the Alpha DaRT, to cancer patients who may not have other attractive treatment alternatives,” added Dr. Pascal Pommier. “This novel application of alpha radiation aims to utilize a focused and highly powerful radiation that may destroy tumors while minimizing toxicity. I found the treatment simple and straightforward, and look forward to helping other patients soon using the Alpha DaRT.”

“With our international clinical study program progressing in several countries, we look forward to producing results on a larger scale in France with Dr. Pascal Pommier and his experienced staff,” said Alpha Tau CMO, Dr. Robert Den.